Clinical News

New Rx, generics, OTC, and devices

Will FDA classify hydrocodone as Schedule III, Schedule II, or somewhere in between?

Guideline-directed medical therapy for heart failure (HF) is highly cost-effective and able to produce significant health gains for individuals with mild to moderate disease, according a study published April 2 in the Journal of the American College of Cardiology.

First new NVP approval in 50 years brings back 30-year-old drug

The antiarrhythmia drug amiodarone appears to be linked to a higher risk of cancer in men, specifically those who receive higher cumulative defined daily doses within the first year of treatment, according to a retrospective study published online April 8 in Cancer.

Ruling clears obstacles judge said were politically influenced

Pharmacists and other healthcare providers are still confusing Prilosec (omeprazole) and Prozac (fluoxetine) prescriptions, according to a new report from the Institute for Safe Medication Practices (ISMP).

A review of the literature provides moderate strength evidence that sublingual immunotherapy is effective for the treatment of allergic rhinitis and asthma, according to an article published March 27 in the JAMA.

The use of extended-release niacin as an adjunct to statins does not reduce the risk of a heart attack or stroke in patients with pre-existing cardiovascular disease, according to researchers who led the HPS2-THRIVE study.

Last year's fungal meningitis outbreak highlighted the importance of an engaged public health system

Multiple prescribers + lack of MTM = a hot mess

FDA is receiving insufficient information and has limited authority to enforce REMS, says OIG report

FDA recently approved apixaban for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

FDA approved bed aquiline tablets late last year for the treatment of pulmonary multi-drug-resistant tuberculosis.